No evidence for cognitive improvement from oral nicotinamide adenine dinucleotide (NADH) in dementia.

M Rainer, E Kraxberger, M Haushofer, H A Mucke, K A Jellinger

Journal: Journal of neural transmission (Vienna, Austria : 1996) 2001;107(12):1475-81

PMID: 11459000

Abstract

Reduced nicotinamide adenine dinucleotide (NADH) is advertised as an over-the-counter product or dietary supplement to treat Alzheimer's disease. We performed a 3-month open-label study with oral 10 mg/day NADH with 25 patients with mild to moderate dementia of the Alzheimer, vascular, and fronto-temporal types in addition to their current cholinomimetic drug medication. In 19 patients who completed the study, we found no evidence for any cognitive effect as defined by established psychometric tests. We conclude that NADH is unlikely to achieve cognitive improvements in an extent reported earlier, and present theoretical arguments against an effectiveness of this compound in dementia disorders.

Address: Memory-Clinic and Psychiatric Department, Donauspital, Sozialmedizinisches Zentrum Ost, Wein, Austria.

DOI: 10.1007/s007020070011

Link outs

Free resources

Medical:

https://medlineplus.gov/alzheimersdisease.html

Subscription / membership required

Full Text Sources:

https://doi.org/10.1007/s007020070011

MeSH Terms: Administration, Oral, Aged, Aged, 80 and over, Alzheimer Disease, Cholinesterase Inhibitors, Cognition, Dementia, Dementia, Vascular, Drug Therapy, Combination, Female, Humans, Language, Male, Memory, Mental Status Schedule, Middle Aged, NAD, Orientation, Psychiatric Status Rating Scales, Psychological Tests, Treatment Failure